Skip to Navigation Skip to Search Skip to Content
Search All Centers

Experts Comment: Lung Cancer Buzz at ASCO 2017

Read Transcript Download/Print Transcript

Published on June 13, 2017

At the 2017 ASCO meeting in Chicago, Host Andrew Schorr meets with noted experts Dr. David Carbone and Dr. George Simon to get an update on lung cancer news at this year's conference. Dr. Carbone and Dr. Simon agree that there is progress being made in lung cancer research across the board. Dr. David Carbone is the Director of the James Thoracic Center at Ohio State University and Dr. George Simon is a Professor in the Department of Thoracic/Head and Neck Medical Oncology in the Division of Cancer Medicine at MD Anderson Cancer Center.

Featuring

Sponsors

Patient Empowerment Network

You might also like

Transcript | ASCO 2017: Newsworthy Treatment and Research Developments in Lung Cancer

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That's how you’ll get care that's most appropriate for you.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Andrew Schorr:

What's the buzz here that would be meaningful in the sort of drumbeat of progress for people living with lung cancer? 

Dr. Carbone:

Well, the buzz for lung cancer is continuing progress in virtually every front of managing the disease.  We have new data being presented on new drugs that are more effective at getting into the brain and preventing and treating brain metastases.  They produce longer remissions.  They have better quality of life for patients.  We have new types of immunotherapy and new indications for immunotherapy being presented, and the progress is across the board and very exciting.  

Andrew Schorr:

Hmm.  What's your view, George? 

Dr. Simon: 

I agree with that entirely.  I think we are making progress on multiple fronts, and in targeted therapies we're getting better drugs, more effective drugs.  In immunotherapies, we are having, getting a better understanding of how best to use them, in what setting, more data on some of the rare thoracic malignancies and the role of immunotherapy in those, novel immunotherapy combinations.  So, yes, I agree with David.  We are having progress, fairly relentless progress on multiple fronts.  

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

You might also like